Form 4: Anika Therapeutics EVP David Colleran Reports Stock Transactions

David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reports the vesting of RSUs and subsequent stock transactions to cover tax obligations.

Summary

• On March 11, 2025, David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, had 7,663 Restricted Stock Units (RSUs) vest.
• These RSUs represent the third and final vesting installment of RSUs granted on March 11, 2022.
• Colleran acquired 7,663 shares of common stock upon vesting of the RSUs.
• 2,250 shares were withheld by Anika Therapeutics to satisfy tax withholding obligations related to the RSU vesting.
• The price per share for the tax withholding was $16.79, which was the closing price of ANIK common stock on March 11, 2025.
• Following these transactions, Colleran directly owns 43,399 shares of Anika Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock transactions, which carries a neutral sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.

Key Dates